

**CATABOLITE REPRESSON CONTROL (*cre*) GENE
AND *PSEUDOMONAS* VIRULENCE**

Paul V. Phibbs, David N. Collier, and Paul W. Hager

Field of the Invention

The present invention concerns methods of screening for active agents useful as an antibacterial agent against *Pseudomonas*, as well as active agents and methods of use thereof in treating *Pseudomonas*.

Background of the Invention

Pseudomonas infection is a leading cause of death in cystic fibrosis, and one of the top causes of serious hospital-acquired infections. *Pseudomonas* infection is particularly serious in burn victims and leukemia patients, and can cause blindness by infection in patients afflicted with trauma to the eye through surgery or contact lenses. Further, *Pseudomonas* has a high intrinsic resistance to current antibiotics. Hence, there is a need for the development of new antibiotics to treat *Pseudomonas* infections.

The use of antisense oligonucleotides in the treatment of bacterial infections is known. U.S. Patent No. 5,294,533 to J. Lupski and L. Katz (assigned to Baylor College of Medicine and Abbott Laboratories, Inc.) describes a method of interrupting the expression of a macromolecular synthesis operon in bacteria comprising the step of binding an antisense oligonucleotide to a single stranded DNA or to a mRNA transcribed from the macromolecular synthesis operon. The antisense oligonucleotide can be either sequence specific to a unique intergenic sequence or a sequence specific to a bacterial homologous sequence. By interrupting the expression of the macromolecular synthesis, it is said that bacterial infections can be treated.

U.S. Patent No. 6,060,241 to I. Cortesy-Theulaz (assigned to Kieta Holding SA) describes a poly-3-hydroxybutyrate metabolic pathway essential for *Helicobacter*

pylori survival in a host. A *Helicobacter pylori* Coenzyme A transferase (Hp CoA-t), thiolase and PHB synthase, as well as methods for their preparation and use are provided. Pharmaceutical compositions containing Hp CoA-t protein fragments, antisense nucleic acids or other inhibitors of Hp CoA-t, thiolase and PHB synthase, as well as methods for their use in the treatment of some types of gastric disease are also described. This reference is not concerned with *Pseudomonas*.

PCT Application WO98/03533A1 to A. Arrow et al. (assigned to Oligos Etc. and Oligos Therapeutics Inc.) describes the general therapeutic use of nuclease resistant oligonucleotides for treating animals having an infection caused by a pathogenic bacterium. The method is a general one and involves the integration of (1) methods for selecting the correct oligonucleotide, (2) synthesis and purification of nuclease resistant oligonucleotides, and (3) methods for in vitro analysis of potential antimicrobial oligonucleotides.

There remains a need for new ways to screen for antibiotics effective against *Pseudomonas*, along with compounds and methods of treating *Pseudomonas* infections.

Summary of the Invention

The present invention provides a method of screening for compounds that inhibit the virulence of *Pseudomonas* bacteria. The method comprises the steps of: providing a culture medium comprising *Pseudomonas* bacteria; administering a test compound to said bacteria; and then detecting the presence or absence of inhibition of the catabolite repression control (Crc) protein in said bacteria, the inhibition of the Crc protein indicating said compound has antivirulence activity against *Pseudomonas* bacteria.

A second aspect of the present invention is an antivirulence compound (for example, an antisense oligonucleotide) that inhibits expression or activity of the Crc protein in a *Pseudomonas* bacteria. Such compounds are useful as antivirulence compounds. When such compounds are antisense oligonucleotides they are preferably from 8 to 25, 40 or 80 nucleotides in length, and preferably are nuclease resistant.

A third aspect of the present invention is an antivirulence compound as described above in a pharmaceutically acceptable carrier.

A fourth further aspect of the present invention is a method of inhibiting the virulence of *Pseudomonas* bacteria, comprising administering to *Pseudomonas* bacteria an antivirulence compound as described above in an effective antivirulence amount. The administering step may be carried out *in vitro*, for example in drug testing or screening studies, or may be carried out *in vivo* in the treatment of a subject.

A further aspect of the present invention is a method of treating *Pseudomonas* infection in a subject in need thereof, comprising administering to said subject an antivirulence compound as described above in an amount effective to treat said *Pseudomonas* infection.

A still further aspect of the present invention is the use of an antivirulence compound as described above for the preparation of a medicament for carrying out a method as described above.

The foregoing and other objects and aspects of the present invention are explained in greater detail in the specification set forth below.

Detailed Description of the Preferred Embodiments

The term "*Pseudomonas*" as used herein refers to any type of *Pseudomonas* bacteria, including but not limited to *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas fluorescens*, and *Pseudomonas multivorans*. Particularly preferred for carrying out the present invention is *Pseudomonas aeruginosa*.

The terms "antivirulence" and "antivirulent" as used herein refers to the activity of a compound in reducing, at least in part, the degree of pathogenicity of a microorganism, as indicated by fatality rate of infected hosts infected with that microorganism and/or the ability of that microorganism to invade the tissues of an infected host.

The term "compound" as used herein refers to a peptide, peptidomimetic, organic, or other chemical molecule, and also refers to a nucleic acid molecule or chemical derivative thereof.

The term "oligonucleotide" herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring

oligonucleotide linkages. Oligonucleotides are usually a polynucleotide subset with 200 bases or fewer in length. Preferably oligonucleotides are minimally 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in minimal length. Oligonucleotides are usually single-stranded, e.g. for probes; 5 although oligonucleotides may be double-stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and 10 the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. An oligonucleotide can include a label for detection, if desired. Peptide nucleic acids (PNAs) are a specific example of oligonucleotides 15 included within the term "oligonucleotide". Examples of peptide nucleic acid structures (in the appropriate sequence as given below), that may be used to carry out the present invention include, but are not limited to, those described in U.S. Patents Nos. 5,986,053; 6,133,444; 6,107,470; 6,015,887; 6,015,710; 5,846,010; 5,773,571; 5,672,584; 5,539,083; and 5,539,082 (applicants specifically intend that the 20 disclosures of all United States patent references cited herein are to be incorporated by reference herein in their entirety).

Subjects with which the present invention is concerned include both human subjects and animal subjects (particularly mammalian subjects such as dogs, cats, horses, cattle) for veterinary purposes.

25

1. Screening methods.

Test compounds, including combinatorial libraries of such compounds, that may be screened for activity by the methods of the invention are, in general, small organic compounds (i.e., non-oligomers), oligomers, or combinations thereof. 30 Compounds which exhibit activity in these methods are referred to as "active compounds" below.

Small organic compounds (or “non-oligomers”) include a wide variety of organic molecules, such as heterocyclics, aromatics, alicyclics, aliphatics and combinations thereof, comprising steroids, antibiotics, enzyme inhibitors, ligands, hormones, drugs, alkaloids, opioids, terpenes, porphyrins, toxins, catalysts, as well as combinations thereof. Libraries of such compounds are available, examples including benzodiazepine libraries as described in U.S. Patent No. 5,288,514; phosphonate ester libraries as described in U.S. Patent No. 5,420,328, pyrrolidine libraries as described in U.S. Patent Nos. 5,525,735 and 5,525,734, and diketopiperazine and diketomorpholine libraries as described in U.S. Patent No. 5,817,751.

Oligomers include oligopeptides, oligonucleotides, oligosaccharides, polylipids, polyesters, polyamides, polyurethanes, polyureas, polyethers, and poly (phosphorus derivatives), e.g. phosphates, phosphonates, phosphoramides, phosphonamides, phosphites, phosphinamides, etc., poly (sulfur derivatives) e.g., sulfones, sulfonates, sulfites, sulfonamides, sulfenamides, etc., where for the phosphorous and sulfur derivatives the indicated heteroatom for the most part will be bonded to C,H,N,O or S, and combinations thereof. Such oligomers may be obtained from combinatorial libraries in accordance with known techniques, or may be designed to have an antisense sequence based upon the known sequence of the Crc gene, such as assigned GenBank accession number L12038 (C. MacGregor et al., *J. Bacteriol.* **178**, 5627-5635 (1996). Examples of such oligonucleotides include, but are not limited to, those having the sequence given herein as **SEQ ID NO:1**, **SEQ ID NO: 2**, **SEQ ID NO: 3**, and **SEQ ID NO: 4**.

As noted above, a method of screening for compounds that inhibit the virulence of *Pseudomonas* bacteria comprises first providing a culture medium comprising *Pseudomonas* bacteria and administering a test compound to said bacteria. The bacterial culture can be provided in any suitable form, such as in a petri dish on a growth medium, and the test compound can be administered to the bacterial culture in any way, such as by diluting the test compound and applying it to colonies of bacteria on a petri dish; mixing bacteria in a solution containing the test compound and then applying those bacteria to a culture medium in a petri dish; etc.

The step of detecting the presence or absence of inhibition of the catabolite repression control (Crc) protein in the bacteria can be carried out directly (e.g., by the

use of oligonucleotide probes for Crc gene expression activity; by isolation and quantification of expressed Crc protein) or indirectly (e.g., by observation of responses mediated by the Crc gene and encoded protein). It will be noted that the detecting step is a selective one: that is, the test compound is not applied in an
5 antibacterial amount to the bacteria, as this would prevent the identification of compounds that selectively inhibit the Crc protein.

A particularly suitable screening assay is one in which fluoroacetamide is used in the bacterial culture. Fluoroacetamide is ordinarily metabolized to fluoroacetic acid by amidase in *Pseudomonas* bacteria, with the fluoroacetic acid being toxic to the
10 bacteria. Amidase operon repressors, which are mediated by crc, reduce the amount of amidase in the cells and thus protect the cells from fluoroacetic acid toxicity. Any suitable amidase operon repressor can be used, including Krebs cycle intermediates and acetate, with succinic acid particularly preferred. Thus, test compounds that inhibit the crc protein can be detected by adding an amidase operon repressor to the
15 culture medium, adding fluoroacetamide to the culture medium, and administering the test compound to the bacteria. Detection of crc inhibition can then be carried out by detecting the poisoning of said bacteria (e.g., death of bacteria, inhibition of bacterial growth or function, etc.) by the fluoroacetamide (specifically, by its toxic degradation product fluoroacetic acid). The poisoning of the bacteria by the fluoroacetamide
20 indicates the test compound has antivirulence activity against *Pseudomonas* bacteria.

2. Active Compounds and Pharmaceutical Formulations.

Active compounds (or "antivirulence compounds") of the present invention are compounds that exhibit antivirulence activity in the screening procedures
25 described above. Such compounds may be oligomers (including antisense oligonucleotides) or nonoligomers.

Antisense oligonucleotides of the invention may comprise any polymeric compound capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-nucleoside interactions, such as Watson-Crick type of
30 base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Antisense compounds of the invention may also contain pendent groups or moieties, either as part of or separate from the basic repeat unit of the polymer, to enhance

specificity, nuclease resistance, delivery, or other property related to efficacy, e.g. cholesterol moieties, duplex intercalators such as acridine, poly-L-lysine, "end capping" with one or more nuclease-resistant linkage groups such as phosphorothioate, and the like. Thus, numerous different "backbone" chemistries, including the peptide nucleic acid chemistries, can be used for the oligonucleotides, as long as the desired or necessary sequence is incorporated into the particular molecule used.

Antisense compounds of the invention include the pharmaceutically acceptable salts thereof, including those of alkaline earths, e.g. sodium or magnesium, ammonium or NX_4^+ , wherein X is C_1 - C_4 alkyl. Other pharmaceutically acceptable salts include organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic, and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, and benzenesulfonic; and inorganic acids such as hydrochloric, sulfuric, phosphoric, and sulfamic acids. Pharmaceutically acceptable salts of a compound having a hydroxyl group include the anion of such compound in combination with a suitable cation such as Na^+ , NH_4^+ , or the like.

Preferably, nuclease resistance is conferred on the antisense compounds of the invention by providing nuclease-resistant internucleosidic linkages. Many such linkages are known in the art, e.g. phosphorothioate: Zon and Geiser, *Anti-Cancer Drug Design*, 6: 539-568 (1991); Stec et al, U.S. Pat. No. 5,151,510; Hirschbein, U.S. Pat. No. 5,166,387; Bergot, U.S. Pat. No. 5,183,885; phosphorodithioates: Marshall et al, *Science*, 259:1564-1570 (1993); Carathers and Nielsen, International application PCT/US89/02293; phosphoramidates, e.g. $--OP(=O)(NR^1 R^2)--O--$ with R^1 and R^2 hydrogen or C_1 - C_3 alkyl: Jager et al, *Biochemistry*, 27:7237-7246 (1988); Froehler et al, International application PCT/US90/03138; peptide nucleic acids: Nielsen et al, *Anti-cancer Drug Design*, 8: 53-63 (1993), International application PCT/EP92/O1220; methylphosphonates: Miller et al, U.S. Pat. No. 4,507,433; Ts'o et al, U.S. Pat. No. 4,469,863; Miller et al, U.S. Pat. No. 4,757,055; and P-chiral linkages of various types, especially phosphorothioates, Stec et al, European patent application 92301950.9 and Lesnikowski, *Bioorganic Chemistry*, 21:127-155 (1993). Additional nuclease linkages include phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, alkylphosphotriester such as methyl- and

ethylphosphotriester, carbonate such as carboxymethyl ester, carbamate, morpholino carbamate, 3'-thioformacetal, silyl such as dialkyl (C₁ -C₆)- or diphenylsilyl, sulfamate ester, and the like. Such linkages and methods for introducing them into oligonucleotides are described in many references, e.g. reviewed generally by Peyman and Ulmann (cited above); Milligan et al (cited above); Matteucci et al, International application PCT/US91/06855. Preferably, phosphorus analogs of the phosphodiester linkage are employed in the compounds of the invention, such as phosphorothioate, phosphorodithioate, phosphoramidate, or methylphosphonate. More preferably, phosphorothioate is employed as the nuclease resistant linkage. It is understood that in addition to the preferred linkage groups, compounds of the invention may comprise additional modifications, e.g. boronated bases, Spielvogel et al, U.S. Pat. No. 5,130,302; cholesterol moieties, Shea et al, Nucleic Acids Research, 18:3777-3783 (1990) or Letsinger et al, Proc. Natl. Acad. Sci., 86:6553-6556 (1989); 5-propenyl modification of pyrimidines, Froehler et al, Tetrahedron Lett., 33: 5307-5310 (1992); and the like.

Other examples of antisense oligonucleotides (i.e., chemical backbone structures) that may be used to carry out the present invention include those described in U.S. Patents Nos. 6,015,866 to Arrow and 5,989,912 to Arrow.

Preferably, antisense compounds of the invention are synthesized by conventional means on commercially available automated DNA synthesizers, e.g. an Applied Biosystems (Foster City, Calif.) model 380B, 392 or 394 DNA/RNA synthesizer. Preferably, phosphoramidite chemistry is employed, e.g. as disclosed in the following references: Beaucage and Iyer, Tetrahedron, 48:2223-2311 (1992); Molko et al, U.S. Pat. No. 4,980,460; Koster et al, U.S. Pat. No. 4,725,677; Caruthers et al, U.S. Pat. Nos. 4,415,732; 4,458,066; and 4,973,679; and the like.

In embodiments where triplex formation is desired, there are constraints on the selection of target sequences. Generally, third strand association via Hoogsteen type of binding is most stable along homopyrimidine-homopurine tracks in a double stranded target. Usually, base triplets form in T-A*T or C-G*C motifs (where "-" indicates Watson-Crick pairing and "*" indicates Hoogsteen type of binding); however, other motifs are also possible. For example, Hoogsteen base pairing permits parallel and antiparallel orientations between the third strand (the Hoogsteen strand)

and the purine-rich strand of the duplex to which the third strand binds, depending on conditions and the composition of the strands. There is extensive guidance in the literature for selecting appropriate sequences, orientation, conditions, nucleoside type (e.g. whether ribose or deoxyribose nucleosides are employed), base modifications (e.g. methylated cytosine, and the like) in order to maximize, or otherwise regulate, triplex stability as desired in particular embodiments, e.g. Roberts et al, Proc. Natl. Acad. Sci., 88:9397-9401 (1991); Roberts et al, Science, 258:1463-1466 (1992); Distefano et al, Proc. Natl. Acad. Sci., 90:1179-1183 (1993); Mergny et al, Biochemistry, A 30:9791-9798 (1991); Cheng et al, I. Am. Chem. Soc., 114:4465-4474 (1992); Beal and Dervan, Nucleic Acids Research, 20:2773-2776 (1992); Beal and Dervan, I. Am. Chem. Soc., 114:4976-4982 (1992); Giovannangeli et al, Proc. Natl. Acad. Sci., 89: 8631-8635 (1992); Moser and Dervan, Science, 238:645-650 (1987); McShan et al, J. Biol. Chem., 267:5712-5721 (1992); Yoon et al, Proc. Natl. Acad. Sci., 89:3840-3844 (1992); Blume et al, Nucleic Acids Research, 20:1777-1784 (1992); and the like.

The length of the oligonucleotide moieties is sufficiently large to ensure that specific binding will take place only at the desired target polynucleotide and not at other fortuitous sites, as explained in many references, e.g. Rosenberg et al, International application PCT/US92/05305; or Szostak et al, Meth. Enzymol. 68:419-429 (1979). The upper range of the length is determined by several factors, including the inconvenience and expense of synthesizing and purifying oligomers greater than about 30-40 nucleotides in length, the greater tolerance of longer oligonucleotides for mismatches than shorter oligonucleotides, whether modifications to enhance binding or specificity are present, whether duplex or triplex binding is desired, and the like. Usually, antisense compounds of the invention have lengths in the range of about 12 to 60 nucleotides. More preferably, antisense compounds of the invention have lengths in the range of about 15 to 40 nucleotides; and most preferably, they have lengths in the range of about 18 to 30 nucleotides.

The antisense oligonucleotides of the invention can be synthesized by any of the known chemical oligonucleotide synthesis methods. Such methods are generally described, for example, in Winnacker, From Genes to Clones: Introduction to Gene Technology. VCH Verlagsgesellschaft mbH (H., Ibelgaufts trans. 1987). Any of the

known methods of oligonucleotide synthesis can be utilized in preparing the instant antisense oligonucleotides. The antisense oligonucleotides are most advantageously prepared by utilizing any of the commercially available, automated nucleic acid synthesizers. The device utilized to prepare the oligonucleotides described herein, the
5 Applied Biosystems 380B DNA Synthesizer, utilizes β -cyanoethyl phosphoramidite chemistry.

Oligonucleotides complementary to and hybridizable with any portion of the Crc gene mRNA transcript are, in principle, effective for inhibiting translation of the transcript, and capable of inducing the effects herein described. Translation is most
10 effectively inhibited by blocking the mRNA at a site at or near the initiation codon. Thus, oligonucleotides complementary to the 5'-terminal region of the Hp CoA-t or thiolase mRNA transcript are preferred. Secondary or tertiary structure which might interfere with hybridization is minimal in this region. The antisense oligonucleotide is preferably directed to a site at or near the ATG initiation codon for protein synthesis.
15 Oligonucleotides complementary to a portion of the Hp CoA-t or thiolase mRNA including the initiation codon are preferred. While antisense oligomers complementary to the 5'-terminal region of the Hp CoA-t or thiolase transcript are preferred, particularly the region including the initiation codon, it should be appreciated that useful antisense oligomers are not limited to those complementary to
20 the sequences found in the translated portion of the mRNA transcript, but also includes oligomers complementary to nucleotide sequences contained in, or extending into, the 5'- and 3'-untranslated regions.

Preferably, the thermal stability of the antisense oligonucleotides of the invention are determined by way of melting, or strand dissociation, curves. The
25 temperature of fifty percent strand dissociation is taken as the melting temperature, T_m , which, in turn, provides a convenient measure of stability. T_m measurements are typically carried out in a saline solution at neutral pH with target and antisense oligonucleotide concentrations at between about 1.0-2.0 μ M. Typical conditions are as follows: 150 mM NaCl and 10 mM $MgCl_2$ in a 10 mM sodium phosphate buffer
30 (pH 7.0) or in a 10 mM Tris-HCl buffer (pH 7.0); or like conditions. Data for melting curves are accumulated by heating a sample of the antisense oligonucleotide/target polynucleotide complex from room temperature to about 85-90° C. As the

temperature of the sample increases, absorbance of 260 nm light is monitored at 1° C. intervals, e.g. using a Cary (Australia) model 1E or a Hewlett-Packard (Palo Alto, Calif.) model HP 8459 UV/VIS spectrophotometer and model HP 89100A temperature controller, or like instruments. Such techniques provide a convenient
5 means for measuring and comparing the binding strengths of antisense oligonucleotides of different lengths and compositions.

In yet another aspect, a pharmaceutical composition comprises a compound that inhibits the activity of the crc protein. Such compound can be identified by any of the methods described above.

10 Pharmaceutical compositions of the invention include a pharmaceutical carrier that may contain a variety of components that provide a variety of functions, including regulation of drug concentration, regulation of solubility, chemical stabilization, regulation of viscosity, absorption enhancement, regulation of pH, and the like. For example, in water soluble formulations the pharmaceutical composition
15 preferably includes a buffer such as a phosphate buffer, or other organic acid salt, preferably at a pH of between about 7 and 8. For formulations containing weakly soluble antisense compounds, microemulsions may be employed, for example by using a nonionic surfactant such as Tween 80 in an amount of 0.04-0.05% (w/v), to increase solubility. Other components may include antioxidants, such as ascorbic
20 acid, hydrophilic polymers, such as, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, dextrans, chelating agents, such as EDTA, and like components well known to those in the pharmaceutical sciences, e.g. Remington's Pharmaceutical Science, latest edition (Mack Publishing Company, Easton, Pa.).

25 An effective amount of oligonucleotide for particular applications depends on several factors, including the chemical nature of the antisense oligonucleotide, the disorder being treated, the method of administration, and the like. Preferably, an effective amount will provide a concentration of oligonucleotide of between about 1 to 100 μ M at the target polynucleotide; and more preferably, an effective amount will
30 provide a concentration of antisense oligonucleotide of between about 1 to 10 μ M at the target polynucleotide.

Depending on the structural and stability characteristics of the active compound, the per unit dosage and precise formulation of the pharmaceutical composition may vary. Typically, such compound would be administered orally at a dose ranging from 0.08 mg to 5 g daily, preferably between 0.2 mg to 0.2 g daily, most preferably between 0.8 mg to 100 mg daily. Preferably the compound would be administered multiple times per day and can be administered in a single dose, although this is less preferred. Typically, the drug delivery vehicle, whether liquid, gel, tablet, or another vehicle, will permit effective release of the compound at the site of infection. The drug delivery vehicle can provide for either immediate release or systematic release over time at the site of infection. The inhibitor compound can be administered parenterally, such as intravenously, but this is less preferred. The compound can also be administered prophylactically to prevent the onset of disease associated with bacterial infection.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as polyvinylpyrrolidone, gum tragacanth, acacia, sucrose, corn starch or gelatin; an excipient such as calcium phosphate, sodium citrate and calcium carbonate; a disintegrating agent such as corn starch, potato starch, tapioca starch, certain complex silicates, alginic acid and the like; a lubricant such as sodium lauryl sulfate, talc and magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, flavoring such as cherry or orange flavor, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. Of course, any material used in

preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.

The present invention is explained in greater detail in the following non-limiting Examples.

5

EXAMPLE 1

Virulence of *crc*⁺ and *crc*⁻

Pseudomonas aeruginosa in a Mouse Burn Model

A wild-type strain of *P. aeruginosa* designated PAO0001, a *crc* point mutation strain of *P. aeruginosa* designated PAO8007, and a *crc* knock-out strain of *P. aeruginosa* designated PAO8020, were tested in a burned mouse model of bacterial virulence. 200 cells of the indicated strain were injected into the burned skin wound of the animals. At 48 hours post burn/infection death was observed in four of the five mice infected with PAO0001. Large numbers of PAO0001 were recovered from skin, blood, liver, spleen and other organs at death. This is similar to the mortality found in other strains of *P. aeruginosa*.

In contrast, only one of five animals infected with PAO8007 was dead 48 hours after burn and infection (again with 200 bacterial cells), and all four remaining animals were still alive 7 days after burn and infection. Similar results were seen with animals infected with PAO8020.

The foregoing study was repeated with PAO8007 and PAO8020, but ten times the usual amount of bacteria was injected into the burn wound (i.e., 2,000 bacterial cells per animal). Essentially the same results were seen.

25

EXAMPLE 2

Fluoroacetamide Plate Assay for Crc

This assay (described in O'Toole et al., *J. Bacteriol.* **182**, 425-431 (2000)) takes advantage of the Crc mediated repression of the amidase operon of *P. aeruginosa* by organic acids. Amidase hydrolyzes the fluoroacetamide into the toxic intermediate fluoroacetic acid. The steps are as follows:

30

(1) streak bacteria onto a BSM minimal (W Lynch and M. Franklin, *Arch. Microbiol.* **118**, 133-140 (1978)) plate containing 40 mM succinate and grow overnight at 37 degrees centigrade.

(2) Restreak bacteria onto BSM minimal containing 40 mM succinate and 2.5
5 mg/ml fluoroacetamide (FAA) (Aldrich 12,834-1). Incubate about 36 hours at 37 degrees. In *crc+* strains, succinate represses the expression of amidase and allows for growth in the presence of FAA. Catabolite repression control –negative (*crc-*) mutant strains express amidase which converts FAA to the toxic intermediate fluoroacetate, hence the mutants do not grow.

10 The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179